NFXF Blog
Featured
These strategies are based on the fundamental principles of time-out, while incorporating adaptations that address the fact that children with Fragile X syndrome have language and attention difficulties that are best accommodated through additional considerations for repetition, consistency, and predictability.
‘Fishing for a Cureʼ Reels in Over $20,000 This Year!
12 mins read
FORE! Fragile X Annual Golf Event Raises over $63,000 (So Far!)
05 mins read
RECONNECT Q&A
Mirum Launches Phase 2 Trial of MRM-3379 for Fragile X Syndrome
03 mins read
All Articles
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] We have experienced a setback with the cancellation of the extension phase of the STX209 drug trials for Fragile X syndrome, and what have been deemed the technical failures of two other ongoing trials of this drug.
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] By now, many of you have heard that Seaside Therapeutics has decided to end the extension of the trial medication Arbaclofen (STX209).